EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted Delivery of VEGF-siRNA to Glioblastoma Using Orientation-Controlled Anti-PD-L1 Antibody-Modified Lipid Nanoparticles

Ayaka Matsuo-Tani, Makoto Matsumoto, Takeshi Hiu iD, Mariko Kamiya iD, Longjian Geng iD, Riku Takayama iD, Yusuke Ushiroda, Naoya Kato iD, Hikaru Nakamura, Michiharu Yoshida, Hidefumi Mukai, Takayuki Matsuo und 1 weitere

Pharmaceutics · 04.10.2025 · 17 (10) · 1298

DOI: 10.3390/pharmaceutics17101298 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 04.10.2025. Verfasst von Ayaka Matsuo-Tani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8588, Japan. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS), JSPS KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Glioblastoma (GBM) is an aggressive primary brain tumor with limited therapeutic options despite multimodal treatment. Small interfering RNA (siRNA)-based therapeutics can silence tumor-promoting genes, but achieving efficient and tumor-specific delivery remains challenging. Lipid nanoparticles (LNPs) are promising siRNA carriers; however, conventional antibody conjugation can impair antigen recognition and complicate manufacturing. This study aimed to establish a modular Fc-binding peptide (FcBP)-mediated post-insertion strategy to enable PD-L1-targeted delivery of VEGF-siRNA via LNPs for GBM therapy.

Methods

Preformed VEGF-siRNA-loaded LNPs were functionalized with FcBP–lipid conjugates, enabling non-covalent anchoring of anti-PD-L1 antibodies through Fc interactions. Particle characteristics were analyzed using dynamic light scattering and encapsulation efficiency assays. Targeted cellular uptake and VEGF gene silencing were evaluated in PD-L1-positive GL261 glioma cells. Anti-tumor efficacy was assessed in a subcutaneous GL261 tumor model following repeated intratumoral administration using tumor volume and bioluminescence imaging as endpoints.

Results

FcBP post-insertion preserved LNP particle size (125.2 ± 1.3 nm), polydispersity, zeta potential, and siRNA encapsulation efficiency. Anti-PD-L1–FcBP-LNPs significantly enhanced cellular uptake (by ~50-fold) and VEGF silencing in PD-L1-expressing GL261 cells compared to controls. In vivo, targeted LNPs reduced tumor volume by 65% and markedly suppressed bioluminescence signals without inducing weight loss. Final tumor weight was reduced by 63% in the anti-PD-L1–FcBP–LNP group (656.9 ± 125.4 mg) compared to the VEGF-siRNA LNP group (1794.1 ± 103.7 mg). The FcBP-modified LNPs maintained antibody orientation and binding activity, enabling rapid functionalization with targeting antibodies.

Conclusions

The FcBP-mediated post-insertion strategy enables site-specific, modular antibody functionalization of LNPs without compromising physicochemical integrity or antibody recognition. PD-L1-targeted VEGF-siRNA delivery demonstrated potent, selective anti-tumor effects in GBM murine models. This platform offers a versatile approach for targeted nucleic acid therapeutics and holds translational potential for treating GBM.

Schlagwörter

Stichwörter der Autor:innen

Fc-binding peptidePD-L1VEGFantibody modificationantibody orientation controlglioblastomalipid nanoparticlessiRNAtargeted drug delivery

Autor:innen und Institutionen

  • Department of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8588, Japan.
  • Department of Neurosurgery, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan.

ORCID-Profile: Takeshi Hiu, Mariko Kamiya, Longjian Geng, Riku Takayama, Naoya Kato, Shigeru Kawakami

Förderung

  • Japan Society for the Promotion of Science (JSPS)
  • JSPS KAKENHI

Zitieren

APA

Matsuo-Tani, A., Matsumoto, M., Hiu, T., Kamiya, M., Geng, L., Takayama, R., Ushiroda, Y., Kato, N., Nakamura, H., Yoshida, M., Mukai, H., Matsuo, T., & Kawakami, S. (2025). Targeted Delivery of VEGF-siRNA to Glioblastoma Using Orientation-Controlled Anti-PD-L1 Antibody-Modified Lipid Nanoparticles. Pharmaceutics, 17(10), 1298. https://doi.org/10.3390/pharmaceutics17101298

Vancouver

Matsuo-Tani A, Matsumoto M, Hiu T, Kamiya M, Geng L, Takayama R, et al. Targeted Delivery of VEGF-siRNA to Glioblastoma Using Orientation-Controlled Anti-PD-L1 Antibody-Modified Lipid Nanoparticles. Pharmaceutics. 2025;17(10):1298. doi:10.3390/pharmaceutics17101298

BibTeX
@article{MatsuoTani2025,
  author = {Matsuo-Tani, Ayaka and Matsumoto, Makoto and Hiu, Takeshi and Kamiya, Mariko and Geng, Longjian and Takayama, Riku and Ushiroda, Yusuke and Kato, Naoya and Nakamura, Hikaru and Yoshida, Michiharu and Mukai, Hidefumi and Matsuo, Takayuki and Kawakami, Shigeru},
  title = {Targeted Delivery of VEGF-siRNA to Glioblastoma Using Orientation-Controlled Anti-PD-L1 Antibody-Modified Lipid Nanoparticles},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {10},
  pages = {1298},
  doi = {10.3390/pharmaceutics17101298}
}
Kostenlos starten →